Autopsy report · NCT01384383
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 248 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Gilead Sciences
- Sponsor type
- Industry
- Conditions
- Chronic Hepatitis C
- Interventions
- GS-5885; GS-9451; RBV; PEG
- Participants
- 248
- Sites
- 55
- Countries
- Australia, Canada, New Zealand, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.